Ackloo Suzanne, Brown Peter J, Müller Susanne
a Structural Genomics Consortium, University of Toronto , Toronto , ON , Canada.
b Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences , Max-von-Laue-Straβe 15, Frankfurt am Main , Germany.
Epigenetics. 2017 May 4;12(5):378-400. doi: 10.1080/15592294.2017.1279371. Epub 2017 Jan 12.
Epigenetic chemical probes are potent, cell-active, small molecule inhibitors or antagonists of specific domains in a protein; they have been indispensable for studying bromodomains and protein methyltransferases. The Structural Genomics Consortium (SGC), comprising scientists from academic and pharmaceutical laboratories, has generated most of the current epigenetic chemical probes. Moreover, the SGC has shared about 4 thousand aliquots of these probes, which have been used primarily for phenotypic profiling or to validate targets in cell lines or primary patient samples cultured in vitro. Epigenetic chemical probes have been critical tools in oncology research and have uncovered mechanistic insights into well-established targets, as well as identify new therapeutic starting points. Indeed, the literature primarily links epigenetic proteins to oncology, but applications in inflammation, viral, metabolic and neurodegenerative diseases are now being reported. We summarize the literature of these emerging applications and provide examples where existing probes might be used.
表观遗传化学探针是一种强效的、具有细胞活性的小分子抑制剂或蛋白质特定结构域的拮抗剂;它们对于研究溴结构域和蛋白质甲基转移酶来说必不可少。结构基因组学联盟(SGC)由来自学术和制药实验室的科学家组成,目前的大多数表观遗传化学探针都是该联盟研发的。此外,SGC已经分享了约4000份这些探针的样品,这些样品主要用于表型分析或验证体外培养的细胞系或原发性患者样本中的靶点。表观遗传化学探针一直是肿瘤学研究中的关键工具,它揭示了对成熟靶点的机制性见解,并确定了新的治疗起点。事实上,文献主要将表观遗传蛋白与肿瘤学联系起来,但现在也有关于其在炎症、病毒、代谢和神经退行性疾病中的应用报道。我们总结了这些新兴应用的文献,并提供了可能使用现有探针的示例。